Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Novonesis (Novozymes) BNVZMF 92 Debt-to-Equity is 0.28 as of Jun. 2026, which is 367% above its 10-year median of 0.06. GuruFocus rates NVZMF with a GF Score™ of 92/100 and a GF Value™ of $67.57 (Fairly Valued). The stock has 5 warning signs investors should review. Among 1,419 Chemicals companies, Novonesis (Novozymes) B ranks better than 55.6% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Novonesis (Novozymes) B's Debt-to-Equity or its related term are showing as below:
NVZMF'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.03 Med: 0.06 Max: 0.52
Current: 0.28
During the past 13 years, the highest Debt-to-Equity Ratio of Novonesis (Novozymes) B was 0.52. The lowest was 0.03. And the median was 0.06.
NVZMF's Debt-to-Equity is ranked better than 55.6% of 1419
companies
in the Chemicals industry
Industry Median: 0.36
vs NVZMF: 0.28
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Novonesis (Novozymes) B Debt-to-Equity Related Terms
Novonesis (Novozymes) B Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Specialty Chemicals subindustry, Novonesis (Novozymes) B's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novonesis (Novozymes) B Debt-to-Equity vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Novonesis (Novozymes) B's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Novonesis (Novozymes) B's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novonesis (Novozymes) B (NVZMF) has a Debt-to-Equity of 0.28 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Novonesis (Novozymes) B and its competitors. This is 367% above median its historical median of 0.06. Over the past decade, Novonesis (Novozymes) B's Debt-to-Equity has ranged from 0.03 to 0.52. According to the industry distribution chart, Novonesis (Novozymes) B ranks #630 out of 1419 companies in the Chemicals industry, placing it in the top 44.4%.
Is Novonesis (Novozymes) B's Debt-to-Equity too high?
Novonesis (Novozymes) B's current Debt-to-Equity of 0.28 is 367% above median its 10-year median of 0.06. Over the past 10 years, this metric has ranged from a low of 0.03 to a high of 0.52. The Chemicals industry median Debt-to-Equity is 0.36. Novonesis (Novozymes) B's value of 0.28 is 22.2% below this industry median. Based on the distribution chart, Novonesis (Novozymes) B ranks #630 out of 1419 companies in the Chemicals industry, which is above the industry midpoint. Overall, Novonesis (Novozymes) B has a GF Score™ of 92/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Novonesis (Novozymes) B's Debt-to-Equity compare to LIN and SHW?
According to the Chemicals industry distribution chart, Novonesis (Novozymes) B ranks #630 out of 1419 companies for Debt-to-Equity. This puts Novonesis (Novozymes) B in the upper half of its industry. The industry median Debt-to-Equity is 0.36. Novonesis (Novozymes) B's value of 0.28 is 22.2% below this benchmark. Historically, Novonesis (Novozymes) B's own Debt-to-Equity has ranged from 0.03 to 0.52 over the past decade. While the company's 10-year median is 0.06 vs. the industry median of 0.36, Novonesis (Novozymes) B has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Chemicals company?
The median Debt-to-Equity among Chemicals companies is 0.36, based on 1,419 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Novonesis (Novozymes) B's current Debt-to-Equity of 0.28 is 22.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Novonesis (Novozymes) B and its competitors. For the Chemicals industry, the median Debt-to-Equity is 0.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novonesis (Novozymes) B's current Debt-to-Equity is 0.28, which is 367% above median its own 10-year median of 0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novonesis (Novozymes) B stock overvalued right now?
Based on GuruFocus' analysis, Novonesis (Novozymes) B (NVZMF) is currently considered Fairly Valued. The stock's GF Value™ is $67.57, compared to a current price of $69.70 — trading 3.2% above its estimated fair value. The current Debt-to-Equity is 0.28, which is 367% above median its 10-year median of 0.06 and 22.2% below the Chemicals industry median of 0.36. Novonesis (Novozymes) B's overall GF Score™ is 92/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Novonesis (Novozymes) B (NVZMF), the current Debt-to-Equity is 0.28 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novonesis (Novozymes) B (NVZMF) Overvalued in 2026?
Based on GuruFocus' analysis, Novonesis (Novozymes) B stock appears to be overvalued.
The current stock price of $69.70 is trading 3.2% above its estimated GF Value™ of $67.57.
GuruFocus considers Novonesis (Novozymes) B to be Fairly Valued.
Key valuation signals for NVZMF:
Debt-to-Equity: 0.28 (367% above median its 10-year median of 0.06)
GF Value™: $67.57 vs. price of $69.70 (3.2% above fair value)
Industry Position: 22.2% below the Chemicals median (#630 of 1419)
No single metric tells the full story. See the NVZMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. Following the merger, the company became the world leader in industrial enzymes and microbial solutions, with a nearly 50% market share in both. The firm supplies a wide range of industry groups: household care, food and beverages, bioenergy, agriculture and feed, technical and pharmaceuticals. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark, employs more than 11,000 people, and works across more than 30 research and development and application centers and 23 manufacturing sites.
92GF Score
Get the complete analysis for NVZMF
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NVZMF has been successfully added to your 
